ADME of biologics-what have we learned from small molecules?

ADME of biologics-what have we learned from small molecules?

Item
http://www.wikidata.org/entity/Q36065589
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentSmall-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesCheminformatic comparison of approved drugs from natural product versus synthetic origins.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Overview on biotherapeutic proteins: impact on bioanalysis.The effect of the neonatal Fc receptor on human IgG biodistribution in mice.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies.Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
P2860

ADME of biologics-what have we learned from small molecules?

Item
http://www.wikidata.org/entity/Q36065589
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ADME of biologics-what have we learned from small molecules?
@ast
ADME of biologics-what have we learned from small molecules?
@en
type
label
ADME of biologics-what have we learned from small molecules?
@ast
ADME of biologics-what have we learned from small molecules?
@en
prefLabel
ADME of biologics-what have we learned from small molecules?
@ast
ADME of biologics-what have we learned from small molecules?
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
ADME of biologics-what have we learned from small molecules?
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932